We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

167 hedge funds and large institutions have $1.41B invested in Coherus Oncology in 2019 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 56 increasing their positions, 43 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more call options, than puts

Call options by funds: $15.8M | Put options by funds: $4.99M

115% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 20

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

30% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 43

14% more funds holding

Funds holding: 146 → 167 (+21)

3.11% more ownership

Funds ownership: 96.32% → 99.43% (+3.1%)

5% less capital invested

Capital invested by funds: $1.47B → $1.41B (-$67.9M)

Holders
167
Holders Change
+21
Holders Change %
+14.38%
% of All Funds
3.66%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
43
Increased
56
Reduced
43
Closed
20
Calls
$15.8M
Puts
$4.99M
Net Calls
+$10.8M
Net Calls Change
+$3.31M

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$26.7M
2
RHJA
Rice Hall James & Associates
California
+$14.1M
3
N
Nuveen
North Carolina
+$13.3M
4
Ameriprise
Ameriprise
Minnesota
+$9.96M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$9.81M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$15.3M
2
JP Morgan Chase
JP Morgan Chase
New York
-$11.8M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$9.99M
4
HP
Hound Partners
New York
-$9.47M
5
DCM
Driehaus Capital Management
Illinois
-$9.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
FIB
151
First Interstate Bank
Montana
$18K +$17.4K +871 New
LTFS
152
Ladenburg Thalmann Financial Services
Florida
$17K +$16K +801 New
HNB
153
Huntington National Bank
Ohio
$17K +$16.9K +844 New
MAM
154
Meeder Asset Management
Ohio
$10K -$325K -16,258 -97%
OIA
155
Optimum Investment Advisors
Illinois
$10K +$9.99K +500 New
Daiwa Securities Group
156
Daiwa Securities Group
Japan
$9K – – –
AS
157
Altshuler Shaham
Israel
$9K +$8.57K +429 New
CTC
158
Central Trust Company
Missouri
$6K +$5.59K +280 New
FMII
159
Farmers & Merchants Investments Inc
Nebraska
$5K +$4.79K +240 New
QT
160
Quantbot Technologies
New York
$5K +$5.91K +296 New
PHK
161
Point72 Hong Kong
Hong Kong
$4K -$8.63K -432 -68%
JCM
162
Jacobi Capital Management
Pennsylvania
$4K – – –
PWMG
163
Prestige Wealth Management Group
New Jersey
$3K +$2.58K +129 New
IA
164
IFP Advisors
Florida
$3K +$2.8K +140 New
RCAG
165
Rehmann Capital Advisory Group
Michigan
$850 +$839 +42 New
DCM
166
Driehaus Capital Management
Illinois
– -$9.38M -424,407 Closed
PC
167
Pier Capital
Connecticut
– -$7.59M -343,308 Closed
FI
168
Fosun International
China
– -$5.12M -238,248 Closed
USAA
169
United Services Automobile Association
Texas
– -$4.8M -217,216 Closed
GTC
170
Ghost Tree Capital
New York
– -$3.87M -175,000 Closed
ECM
171
ExodusPoint Capital Management
New York
– -$2.32M -104,978 Closed
CRC
172
Curi RMB Capital
Illinois
– -$1.83M -82,668 Closed
SSA
173
Schonfeld Strategic Advisors
New York
– -$1.76M -79,600 Closed
EI
174
EAM Investors
California
– -$1.46M -66,041 Closed
CM
175
Caption Management
Oklahoma
– -$999K -50,000 Closed
4 5 6
7
8

CHRS Hedge Fund Activity: Q3 2019 in Review

167 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2019, worth a combined $1.41B — down 4.6% from $1.47B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new CHRS positions and 20 closed out — a net gain of 23 holders — while 56 added to existing stakes and 43 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $26.7M. The largest seller was PFM Health Sciences, cutting an estimated $15.3M.

  • 167 institutional investors held Coherus Oncology (CHRS) as of Q3 2019, up from 146 in Q2 2019.
  • Funds reported $1.41B of Coherus Oncology stock for Q3 2019, down 4.6% quarter-over-quarter.
  • 43 funds opened new Coherus Oncology positions in Q3 2019 and 20 closed out, a net change of +23 holders.
  • The largest Coherus Oncology buyer in Q3 2019 was Rubric Capital Management (New York), an estimated $26.7M added.
  • The largest Coherus Oncology seller in Q3 2019 was PFM Health Sciences, an estimated $15.3M sold.

Based on aggregated 13F filings for Q3 2019.